Tim-3 on natural killer cells regulates immune response via antibody dependent cellular cytotoxicity in HER2-positive gastric cancer
The present study suggests that combined therapy with anti-Tim-3 antibodies and trastuzumab can be a new treatment strategy for HER2-positive GC. Overall design: We performed scRNA-seq analysis from 24 gastric cancers. Please note that the following samples have been included and re-analyzed in the current study: GSE201347/PRJNA830909: GEO sample title SRA Experiment BioSample GSM6061522 gastric cancer [G41T] SRX14976673 SAMN27744099 GSM6061523 gastric cancer [G42T] SRX14976675 SAMN27744098 GSM6061524 gastric cancer [G43T] SRX14976674 SAMN27744097 GSM6061525 gastric cancer [G44T] SRX14976676 SAMN27744096 GSM6061526 gastric cancer [G45T] SRX14976677 SAMN27744095 GSM6061527 gastric cancer [G47T] SRX14976678 SAMN27744094 GSM6061528 gastric cancer [G49T] SRX14976679 SAMN27744093 GSM6061529 gastric cancer [G50T] SRX14976680 SAMN27744092 GSM6061530 gastric cancer [G51T] SRX14976681 SAMN27744091 GSM6061531 gastric cancer [G52T] SRX14976682 SAMN27744090 GSM6061532 gastric cancer [G55T] SRX14976683 SAMN27744089 GSE231539/PRJNA966751: GSM7290598 gastric cancer-Chemotherapy [G54T] SRX20201151 SAMN34550038 GSM7290599 gastric cancer-Chemotherapy [G57T] SRX20201152 SAMN34550037